» Articles » PMID: 28881804

Altered Erythropoiesis and Decreased Number of Erythrocytes in Children with Neuroblastoma

Abstract

Neuroblastoma (NB) is a pediatric tumor presenting at diagnosis either as localized or metastatic disease, which mainly involves the bone marrow (BM). The physical occupancy of BM space by metastatic NB cells has been held responsible for impairment of BM function. Here, we investigated whether localized or metastatic NB may alter hematopoietic lineages' maturation and release of mature cells in the periphery, through gene expression profiling, analysis of BM smears, cell blood count and flow cytometry analysis. Gene ontology and disease-associated analysis of the genes significantly under-expressed in BM resident cells from children with localized and metastatic NB, as compared to healthy children, indicated anemia, blood group antigens, and heme and porphyrin biosynthesis as major functional annotation clusters. Accordingly, in children with NB there was a selective impairment of erythrocyte maturation at the ortho-chromic stage that resulted in reduced erythrocyte count in the periphery, regardless of the presence of metastatic cells in the BM. By considering all NB patients, low erythrocyte count at diagnosis associated with worse survival. Moreover, in the subset of metastatic patients, low erythrocyte count, hemoglobin and hematocrit and high red cell distribution width at follow-up also associated with worse outcome. These observations provide an alternative model to the tenet that infiltrating cells inhibit BM functions due to physical occupancy of space and may open a new area of research in NB to understand the mechanism(s) responsible for such selective impairment.

Citing Articles

The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic Approaches.

Polychronopoulos P, Bedoya-Reina O, Johnsen J Cancers (Basel). 2024; 16(10).

PMID: 38791942 PMC: 11119056. DOI: 10.3390/cancers16101863.


Targeting the myeloid microenvironment in neuroblastoma.

Stip M, Teeuwen L, Dierselhuis M, Leusen J, Krijgsman D J Exp Clin Cancer Res. 2023; 42(1):337.

PMID: 38087370 PMC: 10716967. DOI: 10.1186/s13046-023-02913-9.


Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients.

Voglino V, Persano G, Crocoli A, Castellano A, Serra A, Giordano U Front Pediatr. 2021; 9:761896.

PMID: 34869118 PMC: 8635199. DOI: 10.3389/fped.2021.761896.


Molecular Genetics in Neuroblastoma Prognosis.

Lerone M, Ognibene M, Pezzolo A, Martucciello G, Zara F, Morini M Children (Basel). 2021; 8(6).

PMID: 34072462 PMC: 8226597. DOI: 10.3390/children8060456.


Bone Marrow Environment in Metastatic Neuroblastoma.

Brignole C, Pastorino F, Perri P, Amoroso L, Bensa V, Calarco E Cancers (Basel). 2021; 13(10).

PMID: 34069335 PMC: 8158729. DOI: 10.3390/cancers13102467.


References
1.
Molenaar J, Koster J, Zwijnenburg D, van Sluis P, Valentijn L, van der Ploeg I . Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012; 483(7391):589-93. DOI: 10.1038/nature10910. View

2.
Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

3.
Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M . Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009; 45(16):2835-42. DOI: 10.1016/j.ejca.2009.06.010. View

4.
Irwin M, Park J . Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2014; 62(1):225-56. DOI: 10.1016/j.pcl.2014.09.015. View

5.
Stigliani S, Scaruffi P, Lagazio C, Persico L, Carlini B, Varesio L . Deregulation of focal adhesion pathway mediated by miR-659-3p is implicated in bone marrow infiltration of stage M neuroblastoma patients. Oncotarget. 2015; 6(15):13295-308. PMC: 4537015. DOI: 10.18632/oncotarget.3745. View